Brenig Therapeutics launches first-in-human trial of novel neurodegenerative therapy

The Phase 1 single and multiple ascending dose study is set to begin dosing in early Q1 2026

Exciva initiates Phase 2/3 SERENADA trial for Alzheimer’s agitation therapy

The company doses first patient in US study of Deraphan, as Dolby Ventures joins €53M Series B to support neuropsychiatric innovation

Metropolis Healthcare launches blood-based test for early Alzheimer’s detection

New minimally invasive biomarker test enables earlier diagnosis and improved clinical decision-making, aligned with global guidelines

Marengo Asia launches functional neurosurgery centre, dance therapy for Parkinson’s care

The hospital said the new centre will improve access to specialised interventions such as Deep Brain Stimulation

Alpha Cognition secures key US patent for traumatic brain injury treatment

The patent, titled “ALPHA-1062 for treating Traumatic Brain Injury,” strengthens Alpha Cognition’s existing portfolio supporting both ALPHA-1062 and ZUNVEYL

Lilly to acquire sleep drug biotech firm Centessa in $6.3 billion deal

The company’s broader OX2R portfolio includes clinical and preclinical assets with potential applications across neurological, neurodegenerative, and neuropsychiatric conditions

Amydis bags $2.5 million NIH grant to develop first eye test for key ALS biomarker

IRLAB Therapeutics doses first patient in pivotal apathy trial

The LIFT-PD study will enroll 75 Parkinson’s patients experiencing apathy across 16 sites in Germany, Bulgaria, Poland and Spain

iRegene doses first US Parkinson’s patient, launches landmark MSA trial in China

The move follows encouraging Phase I data and a series of regulatory wins from the U.S. Food and Drug Administration

biomodal expands multiomic reach with Element Biosciences pact

The collaboration merges biomodal’s 5-base and 6-base sequencing solutions, duet +modC and duet evoC